Quarterly report pursuant to Section 13 or 15(d)

Capital Stock

v3.19.3
Capital Stock
6 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Capital Stock

During the six months ended September 30, 2019, we did not engage in any capital-raising transactions, nor did we grant any equity securities as full or partial compensation to consultants, other than stock options as described in Stock-Based Compensation in Note 3, Summary of Significant Accounting Policies.

 

Warrants Outstanding

 

During the quarter ended June 30, 2019, warrants issued in private placement transactions during calendar 2018 to purchase an aggregate of 805,800 shares of our common stock at exercise prices between $1.50 per share and $1.75 per share became fully-exercisable in accordance with their terms. Accordingly, all warrants outstanding at September 30, 2019 are now fully-exercisable at a weighted average exercise price of $2.43 per share as follows:

 

   Exercise         Weighted   Warrants Outstanding  
     Price           Average   Expiration   and Exercisable at  
   per Share     per Share  

Date

  September 30, 2019  
                   
  $ 1.50     $ 1.50   11/30/2021 to 12/13/2022     14,335,200  
  $ 1.59 - $1.80     $ 1.67   2/28/2022 to 10/10/2022     625,619  
  $ 1.82     $ 1.82   3/7/2023     1,388,931  
  $ 2.00 - $3.51     $ 2.14   4/30/2021 to 10/19/2022     696,693  
  $ 5.30     $ 5.30   5/16/2021     2,705,883  
  $ 6.00 - $10.00     $ 7.15   10/11/2019 to 3/3/2023     1,490,628  
          $ 2.43         21,242,954  

 

Of the warrants outstanding at September 30, 2019, 2,705,883 shares of common stock underlying the warrants exercisable at $5.30 per share issued in our May 2016 public offering, 1,388,931 shares of common stock underlying the warrants exercisable at $1.82 per share issued in our September 2017 public offering and 9,596,200 shares of common stock underlying the warrants exercisable at $1.50 per share issued in our December 2017 public offering are registered for resale by the warrant holders. The common shares issuable upon exercise of our remaining outstanding warrants are unregistered. At September 30, 2019, none of our outstanding warrants are subject to down round anti-dilution protection features and all of the outstanding warrants are exercisable by the holders only by payment in cash of the stated exercise price per share.